ResMed Inc. (RMD): Price and Financial Metrics


ResMed Inc. (RMD): $238.44

-2.41 (-1.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RMD POWR Grades


  • Growth is the dimension where RMD ranks best; there it ranks ahead of 93.11% of US stocks.
  • The strongest trend for RMD is in Growth, which has been heading up over the past 179 days.
  • RMD's current lowest rank is in the Momentum metric (where it is better than 16.1% of US stocks).

RMD Stock Summary

  • RMD has a higher market value than 92.44% of US stocks; more precisely, its current market capitalization is $36,152,029,802.
  • With a one year PEG ratio of 525.18, Resmed Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.62% of US stocks.
  • The price/operating cash flow metric for Resmed Inc is higher than 92.04% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Resmed Inc are A, TTWO, CERN, HOLX, and ABMD.
  • RMD's SEC filings can be seen here. And to visit Resmed Inc's official web site, go to www.resmed.com.

RMD Valuation Summary

  • RMD's price/sales ratio is 13.2; this is 16.3% higher than that of the median Healthcare stock.
  • RMD's EV/EBIT ratio has moved down 23.1 over the prior 243 months.
  • RMD's price/earnings ratio has moved down 88.4 over the prior 243 months.

Below are key valuation metrics over time for RMD.

Stock Date P/S P/B P/E EV/EBIT
RMD 2021-08-31 13.2 14.7 89.2 47.2
RMD 2021-08-30 13.2 14.6 88.7 46.9
RMD 2021-08-27 13.1 14.5 88.1 46.6
RMD 2021-08-26 13.0 14.4 87.5 46.3
RMD 2021-08-25 13.0 14.4 87.7 46.4
RMD 2021-08-24 12.9 14.2 86.7 45.8

RMD Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 47.8%.
  • Its 4 year revenue growth rate is now at 63.08%.
  • The 5 year revenue growth rate now stands at 63.08%.
RMD's revenue has moved up $1,670,629,000 over the prior 70 months.

The table below shows RMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 3,443.759 577.025 521.983
2021-09-30 3,348.896 527.062 499.746
2021-06-30 3,196.825 736.718 474.505
2021-03-31 3,091.066 840.458 457.24
2020-12-31 3,091.754 883.875 698.858
2020-09-30 3,027.9 783.891 679.898

RMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RMD has a Quality Grade of C, ranking ahead of 68.39% of graded US stocks.
  • RMD's asset turnover comes in at 0.72 -- ranking 50th of 186 Medical Equipment stocks.
  • PEYE, MMSI, and SIEN are the stocks whose asset turnover ratios are most correlated with RMD.

The table below shows RMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.720 0.569 0.426
2021-06-30 0.691 0.575 0.410
2021-03-31 0.673 0.582 0.379
2020-12-31 0.676 0.582 0.342
2020-09-30 0.670 0.583 0.321
2020-06-30 0.672 0.581 0.300

RMD Price Target

For more insight on analysts targets of RMD, see our RMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $261.67 Average Broker Recommendation 1.91 (Hold)

RMD Stock Price Chart Interactive Chart >

Price chart for RMD

RMD Price/Volume Stats

Current price $238.44 52-week high $301.34
Prev. close $240.85 52-week low $189.40
Day low $231.19 Volume 214,607
Day high $240.69 Avg. volume 586,608
50-day MA $221.15 Dividend yield 0.7%
200-day MA $235.32 Market Cap 34.88B

ResMed Inc. (RMD) Company Bio


ResMed is a San DiegoCalifornia-based medical device company. It primarily provides cloud-connectable CPAP devices and masks for the treatment of sleep apnea, as well as devices and masks for treating chronic obstructive pulmonary disease (COPD), neuromuscular disease, and other respiratory-related conditions. It also provides a self-monitoring digital sensor and app for people who use inhalers to treat COPD or asthma via Propeller Health, which ResMed acquired in 2019. (Source:Wikipedia)  


RMD Latest News Stream


Event/Time News Detail
Loading, please wait...

RMD Latest Social Stream


Loading social stream, please wait...

View Full RMD Social Stream

Latest RMD News From Around the Web

Below are the latest news stories about Resmed Inc that investors may wish to consider to help them evaluate RMD as an investment opportunity.

3 Beaten-Down Growth Stocks With More Than 50% Upside Potential

The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions.

Jaimini Desai on InvestorPlace | February 25, 2022

ResMed Inc. Consensus Indicates Potential 14.4% Upside

ResMed Inc. found using ticker (RMD) have now 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 312 and 235 calculating the mean target price we have 268. With the stocks previous close at 234.24 this is indicating there is a potential upside of 14.4%. There is a 50 day moving average of 245.2 while the 200 day moving average is 252.14. The market cap for the company is $33,887m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets=RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $38,771m based on the market concensus. ResMed Inc. develops, man...

DirectorsTalk | February 20, 2022

ResMed Announces Participation in the Citi Healthcare Conference

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Citi Healthcare Conference on Wednesday, February 23, 2022, beginning at approximately 12:30 p.m. (Eastern Standard Time) via webcast.

GlobeNewswire | February 16, 2022

ResMed Inc. Consensus Indicates Potential 9.7% Upside

ResMed Inc. with ticker code (RMD) have now 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 312 and 235 and has a mean target at 268. With the stocks previous close at 244.35 this is indicating there is a potential upside of 9.7%. The day 50 moving average is 247.85 and the 200 day MA is 251.08. The company has a market capitalisation of $35,669m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" symbol="RMD" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $39,122m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical device...

DirectorsTalk | February 13, 2022

ResMed declares go ex dividend tomorrow

No summary available.

Seeking Alpha | February 8, 2022

Read More 'RMD' Stories Here

RMD Price Returns

1-mo 9.25%
3-mo 21.12%
6-mo -2.04%
1-year -12.75%
3-year 81.11%
5-year 247.35%
YTD -8.10%
2021 23.41%
2020 38.33%
2019 37.85%
2018 36.38%
2017 39.06%

RMD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RMD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6632 seconds.